INVESTORS are poised for a new high on the London market after a company which specialises in cannabis unveiled plans to float.
GW Pharmaceuticals, the only company to legally develop and produce cannabis-based drugs, is seeking admission to the Alternative Investment Market at the end of June.
The Salisbury-based group was founded in 1998 and has already run clinical trials for treatment of multiple sclerosis, spinal cord injury and rheumatoid arthritis.
It wants to raise £16m from the listing to expand clinical trials and up its international reach.
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereComments are closed on this article